157 related articles for article (PubMed ID: 24359127)
21. Sarcoidosis associated with vemurafenib.
Adam A; Thomas L; Bories N; Zaharia D; Balme B; Freymond N; Dalle S
Br J Dermatol; 2013 Jul; 169(1):206-8. PubMed ID: 23834124
[No Abstract] [Full Text] [Related]
22. Successful desensitization in a case of Stevens-Johnson syndrome due to vemurafenib.
Minor DR; Rodvien R; Kashani-Sabet M
Melanoma Res; 2012 Oct; 22(5):410-1. PubMed ID: 22828249
[TBL] [Abstract][Full Text] [Related]
23. Toxic epidermal necrolysis as a complication of treatment with celecoxib.
Perna AG; Woodruff CA; Markus RF; Hsu S
Dermatol Online J; 2003 Dec; 9(5):25. PubMed ID: 14996398
[No Abstract] [Full Text] [Related]
24. Vemurafenib-induced panniculitis.
Villani AP; Zaharia D; Dalle S; Depaepe L; Balme B; Thomas L
Eur J Dermatol; 2013 Apr; 23(2):258-60. PubMed ID: 23567624
[No Abstract] [Full Text] [Related]
25. Vemurafenib and cobimetinib-induced toxic epidermal necrolysis in a patient with metastatic melanoma.
Poduje S; Brozić JM; Prkačin I; Delaš Aždajić M; Goren A
Dermatol Ther; 2020 Jan; 33(1):e13174. PubMed ID: 31750971
[TBL] [Abstract][Full Text] [Related]
26. Stevens-Johnson syndrome/toxic epidermal necrolysis in a patient receiving concurrent radiation and gemcitabine.
Sommers KR; Kong KM; Bui DT; Fruehauf JP; Holcombe RF
Anticancer Drugs; 2003 Sep; 14(8):659-62. PubMed ID: 14501389
[TBL] [Abstract][Full Text] [Related]
27. Tinea hidden by a vemurafenib-induced phototoxic reaction in a patient with metastatic melanoma taking dexamethasone.
Anforth R; Carlos G; Eiris N; Clements A; Fernandez-Peñas P
Med J Aust; 2015 Jul; 203(1):41-2. PubMed ID: 26126567
[No Abstract] [Full Text] [Related]
28. Vemurafenib (Zelboraf) with longer follow-up. Metastatic melanoma: a few extra months of life, but many adverse effects.
Prescrire Int; 2015 Apr; 24(159):89-90. PubMed ID: 25941696
[TBL] [Abstract][Full Text] [Related]
29. Case of vemurafenib-induced Sweet's syndrome.
Yorio JT; Mays SR; Ciurea AM; Cohen PR; Wang WL; Hwu WJ; Gonzalez N; Richard JL; Kim KB
J Dermatol; 2014 Sep; 41(9):817-20. PubMed ID: 24617955
[TBL] [Abstract][Full Text] [Related]
30. Vemurafenib in the French temporary authorization for use metastatic melanoma cohort: a single-centre trial.
Fennira F; Pagès C; Schneider P; Sidina I; Viguier M; Basset-Seguin N; Madjlessi-Ezra N; Madelaine I; Bagot M; Battistella M; Porcher R; Mourah S; Lebbé C
Melanoma Res; 2014 Feb; 24(1):75-82. PubMed ID: 24241686
[TBL] [Abstract][Full Text] [Related]
31. Vemurafenib-induced hypertension: is it real?
Balakan O; Babacan T; Altundag K
J BUON; 2013; 18(2):545. PubMed ID: 23818377
[No Abstract] [Full Text] [Related]
32. Vemurafenib: in unresectable or metastatic melanoma.
Keating GM
BioDrugs; 2012 Oct; 26(5):325-34. PubMed ID: 22946753
[TBL] [Abstract][Full Text] [Related]
33. Reduced expression of the ATP2A2 gene in vemurafenib-induced keratoacanthoma-like papules in a melanoma patient.
Wakimoto H; Harada K; Arai T; Maeda T; Irisawa R; Tsuboi R
Int J Dermatol; 2017 Feb; 56(2):e33-e35. PubMed ID: 27805257
[No Abstract] [Full Text] [Related]
34. Posterior reversible encephalopathy syndrome due to combination of vemurafenib and cobimetinib for metastatic melanoma.
Boukari F; Dugourd PM; Chassang M; Mondot L; Passeron T; Lacour JP; Montaudie H
Pigment Cell Melanoma Res; 2017 Mar; 30(2):262-264. PubMed ID: 27885826
[No Abstract] [Full Text] [Related]
35. Toxic Epidermal Necrolysis-like Reaction With Severe Satellite Cell Necrosis Associated With Nivolumab in a Patient With Ipilimumab Refractory Metastatic Melanoma.
Nayar N; Briscoe K; Fernandez Penas P
J Immunother; 2016 Apr; 39(3):149-52. PubMed ID: 26938948
[TBL] [Abstract][Full Text] [Related]
36. Cumulative dermatologic toxicity with ipilimumab and vemurafenib responsive to corticosteroids.
Ludlow SP; Pasikhova Y
Melanoma Res; 2013 Dec; 23(6):496-7. PubMed ID: 24025700
[TBL] [Abstract][Full Text] [Related]
37. Hidradenitis suppurativa, eruptive melanocytic nevi, and keratosis pilaris-like eruption in a patient treated with vemurafenib.
Ma L; Dominguez AR; Collins GR; Kia KF; Cockerell CJ
Arch Dermatol; 2012 Dec; 148(12):1428-9. PubMed ID: 23247496
[No Abstract] [Full Text] [Related]
38. Delayed oral toxicity from long-term vemurafenib therapy.
Lloyd-Lavery A; Hodgson T; Coupe N; Bond S; Shah K; Espinosa O; Payne MJ; Middleton MR; Matin RN
Br J Dermatol; 2016 May; 174(5):1159-60. PubMed ID: 26853702
[No Abstract] [Full Text] [Related]
39. Vemurafenib-induced neutrophilic panniculitis.
Monfort JB; Pagès C; Schneider P; Neyns B; Comte C; Bagot M; Vignon-Pennamen MD; Viguier M; Lebbé C
Melanoma Res; 2012 Oct; 22(5):399-401. PubMed ID: 22828248
[TBL] [Abstract][Full Text] [Related]
40. Vemurafenib-induced eccrine squamous syringometaplasia.
Lescoat A; Droitcourt C; Stock N; Le Gall F; Dupuy A
Dermatology; 2013; 226(4):362-4. PubMed ID: 23860306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]